日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Matricellular protein SMOC2 safeguards tubular integrity in acute kidney injury via integrin β3-dependent inhibition of CCND1-CDK4/6 axis

基质细胞蛋白SMOC2通过整合素β3依赖性抑制CCND1-CDK4/6轴,在急性肾损伤中维持肾小管完整性。

Gao, Peng; Cenatus, Schrodinger; Zhang, Dan; Chu, Siwei; Henley, Nathalie; Pichette, Vincent; Barrera-Chimal, Jonatan; Gerarduzzi, Casimiro

COSMO-RS guided screening of deep eutectic solvents and ultrasound-assisted extraction for resveratrol from Polygonum cuspidatum

利用 COSMO-RS 指导筛选低共熔溶剂和超声辅助提取虎杖中白藜芦醇

Lu, Yitong; Song, Zimeng; Chen, Pengjun; Sheng, Zunlai; Wu, Zhiyong

Uveal melanoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up

葡萄膜黑色素瘤:ESMO-EURACAN临床实践指南(诊断、治疗和随访)

Piperno-Neumann, S; Angi, M; Ascierto, P A; Baurain, J F; Burgmans, M C; Cassoux, N; Coupland, S E; Dendale, R; Fortuna, A; Gastaud, L; Gutierrez-Miguelez, C; Heegaard, S; Jager, M J; Kapiteijn, E; Keilholz, U; Kilic, E; Marinkovic, M; Moulin, A; Nathan, P; Patel, S P; Pica, A; Piulats, J M; Ryll, B; Sacco, J J; Sauerwein, W; Schlaak, M; Stedman, B; Valente, A; Verdijk, R M; Verhoef, C; Michielin, O

Corrigendum to 'Lazertinib with stereotactic body radiotherapy in oligometastatic EGFR-mutant non-small-cell lung cancer': [ESMO Open. Volume 11, Issue 2, February 2026, 106057]

对“Lazertinib联合立体定向放射治疗寡转移性EGFR突变型非小细胞肺癌”的更正:[ESMO Open. 第11卷,第2期,2026年2月,106057]

Lee, J B; Kim, K H; Yoon, S; Song, S Y; Lee, S S; Jo, S; Ahn, H K; Kim, H J; Choi, S J; Park, H; Hong, M H; Cho, B C; Yoon, H I; Lim, S M

Corrigendum to 'Improving chemotherapy-induced peripheral neuropathy in cancer patients using a combined qigong and self-administered acupressure intervention: a randomized controlled trial': [ESMO Open Volume 10, Issue 9, September 2025, 105565]

对“采用气功和自我穴位按摩相结合的干预措施改善癌症患者化疗引起的周围神经病变:一项随机对照试验”的更正:[ESMO Open 第 10 卷,第 9 期,2025 年 9 月,105565]

Cheung, D S T; Yeung, W F; Chau, P H; Chan, S Y; Chan, W L; Yeh, C H; Lao, L; Zhang, Z; Lin, C C

Corrigendum to "A phase II study of intrapatient dose escalation of biweekly trifluridine/tipiracil plus bevacizumab for colorectal cancer (E-BiTS study)": [ESMO Open. Volume 10, Issue 9, (September 2025) 105571]

关于“结直肠癌患者体内剂量递增的双周三氟尿苷/替吡嘧啶联合贝伐珠单抗 II 期研究(E-BiTS 研究)”的更正:[ESMO Open. 第 10 卷,第 9 期,(2025 年 9 月)105571]

Wakabayashi, M; Taniguchi, H; Makiyama, A; Sunakawa, Y; Takeda, H; Arimizu, K; Okumura, Y; Inagaki, C; Mitani, S; Kudo, T; Yuki, S; Akazawa, N; Kudo, C; Mori, K; Matsuda, T; Muro, K

Corrigendum to "Adjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028": [ESMO Open 10 (2025) 104295]

对“可切除黑色素瘤现代治疗中的辅助免疫疗法:现状及2028年展望”的更正:[ESMO Open 10 (2025) 104295]

Donia, M; Jespersen, H; Jalving, M; Lee, R; Eriksson, H; Hoeller, C; Hernberg, M; Gavrilova, I; Kandolf, L; Liszkay, G; Helgadottir, H; Zhukavets, A; Pjanova, D; Marquez-Rodas, I; Neyns, B; Westgeest, H; Pourmir, I; Sobczuk, P; Ellebaek, E; Amaral, T

Erratum to "Identifying predictors of treatment response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-negative breast cancer: the NEOENDO translational study": [ESMO Open 9 (2024) 103989]

更正“识别激素受体阳性/HER2阴性乳腺癌新辅助化疗和内分泌治疗引起的治疗反应和分子变化的预测因子:NEOENDO转化研究”:[ESMO Open 9 (2024) 103989]

Schettini, F; Brasó-Maristany, F; Pascual, T; Lorman-Carbó, N; Nucera, S; Bergamino, M; Galván, P; Conte, B; Seguí, E; García Fructuoso, I; Gómez Bravo, R; Rodríguez, A B; Martínez-Sáez, O; Chic, N; Vidal, M; Adamo, B; González-Farre, B; Sanfeliu, E; Cebrecos, I; Mensión, E; Oses, G; Locci, M; Mollà, M; Ganau, S; Jares, P; Vidal-Sicart, S; Muñoz, M; Prat, A

ESMO Clinical Practice Guideline Express Update on the adoption of physical exercise in patients with localised colon cancer

ESMO临床实践指南快速更新:局部结肠癌患者采用体育锻炼

Pentheroudakis, G; Argilés, G; Arnold, D; Smyth, E; Ducreux, M

The ESMO/SIOG Cancer in the Elderly Working Group pragmatic strategies for clinical trial designs and endpoints in older adults with cancer

ESMO/SIOG老年癌症工作组针对老年癌症患者临床试验设计和终点的实用策略

Baldini, C; Mislang, A R A; Cheung, K-L; Pilleron, S; Wildiers, H; Rostoft, S; Neuendorff, N R; Frelaut, M; Kanesvaran, R; Papamichael, D; O'Hanlon, S; Puts, M; Canoui-Poitrine, F; Dal Lago, L; Soo, W K; O'Donovan, A; Gomes, F; Cooper, L; Canin, B; Bringuier, M; Battisti, N M L; Biganzoli, L; Brain, E